Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

Bridging the gap: from awareness to action in health equity

The real challenge to achieving health equity lies in translating awareness into tangible action

- PMLiVE

Insights From ISPOR 2025: Breaking the Data Barrier in Rare Diseases – Can AI Bridge the Gap?

Last month, the ISPOR annual meeting in Montreal was brimming with opportunities to explore the latest developments and insights in health economics and outcomes research (HEOR) and market access. In...

Petauri Evidence

- PMLiVE

Medscape Education Celebrates 30 Years of Impact with Launch of The Center of Excellence for Instructional Design

Medscape Education, a global leader in healthcare education, proudly announces the official launch of its Center of Excellence for Instructional Design—a central hub of expertise and strategic capability, dedicated to...

Medscape Education

- PMLiVE

Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer

More than 72,680 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

AstraZeneca and CSPC Pharmaceuticals enter AI-driven partnership worth $5.3bn

The deal will focus on advancing pre-clinical candidates for chronic conditions

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults

The vaccine is already approved in the US for use in adults aged 60 years and older

- PMLiVE

Duchenne muscular dystrophy – diagnosis, clinical development and global research

Its impact on patients, available treatments and why early diagnosis is essential

- PMLiVE

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

- PMLiVE

GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

The decision means that eligible patients in England will be the first in the world to access the combination

- PMLiVE

FDA approves tablet formulation of BeOne’s targeted cancer drug Brukinsa

The new formulation has been authorised for all five indications covered by the original capsule version

- PMLiVE

Patient partnerships for life

It’s not about just engaging with patients, it is about co-creating with patients, making them integral at every stage

Virtual Grant Writing & Review – Engaging Your Advisors Creatively

Boost your research initiatives! Discover how to creatively manage virtual grant writing & review programs with your KOLs, identifying key topics & streamlining proposal approvals. Foster impactful collaborations. Watch

Impetus Digital

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links